Name (Synonyms) | Correlation | |
---|---|---|
drug31 | 2: Usual practice + SYMBICORT RAPIHALER Wiki | 1.00 |
drug985 | Gam-COVID-Vac Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D012120 | Respiration Disorders NIH | 0.29 |
D012140 | Respiratory Tract Diseases NIH | 0.24 |
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
We hypothesize that inhaled steroid therapy and long acting beta 2 adrenergic agonist, widely prescribed in asthma patients, may also have a local protective effect against coronavirus infection, even in patients without asthma. The primary purpose is To compare time to clinical improvement in patients receiving standard of care associated to the combination budesonide/formoterol or standard of care only. Time (in days) to clinical improvement is defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first within 30 days.
Description: Time (in days) to clinical improvement is defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first within 30 days. The seven-category ordinal scale consisted of the following categories: Not hospitalized with resumption of normal activities Not hospitalized, but unable to resume normal activities Hospitalized, not requiring supplemental oxygen Hospitalized, requiring supplemental oxygen Hospitalized, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; Hospitalized, requiring ECMO, invasive mechanical ventilation, or both Death. These parameters will be evaluated daily during hospitalization.
Measure: Time (in days) to clinical improvement within 30 days after randomization Time: within 30 days